Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

被引:107
|
作者
Kuhle, J. [1 ]
Leppert, D. [1 ]
Petzold, A. [4 ,5 ]
Regeniter, A. [2 ]
Schindler, C. [3 ]
Mehling, M. [1 ]
Anthony, D. C. [6 ]
Kappos, L. [1 ]
Lindberg, R. L. P. [1 ]
机构
[1] Univ Basel Hosp, Dept Biomed & Neurol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Lab Med, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Inst Social & Prevent Med, CH-4031 Basel, Switzerland
[4] UCL Inst Neurol, Dept Neuroimmunol, London, England
[5] Free Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Univ Oxford, Dept Pharmacol, Oxford OX1 2JD, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会; 新加坡国家研究基金会;
关键词
HUMORAL IMMUNE-RESPONSE; AXONAL DAMAGE MARKERS; CEREBROSPINAL-FLUID; BIOLOGICAL MARKERS; SYSTEM ATROPHY; PROTEIN-LEVELS; LIGHT-CHAIN; BLOOD; DEGENERATION; BIOMARKER;
D O I
10.1212/WNL.0b013e31821432ff
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Neurodegeneration is now accepted as a pathologic hallmark of multiple sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease activity, or specific stages of MS. Methods: An electrochemiluminescence immunoassay was used to retrospectively measure NfHSMI35 in CSF of patients with clinically isolated syndrome (CIS) (n = 63), relapsing-remitting multiple sclerosis (RRMS) (n = 39), secondary progressive multiple sclerosis (SPMS) (n = 25), primary progressive multiple sclerosis (PPMS) (n = 23), or controls (n = 73). Cell count and CSF levels of immunoglobulin and albumin were also measured. Results: CSF levels of NfH(SMI35) increased with age in controls (r(s) = 0.50, p < 0.0001) and CIS (r(s) = 0.50, p < 0.0001); this effect was less pronounced in RRMS (r(s) = 0.35, p = 0.027) and absent in SPMS/PPMS. After age correction, NfH(SMI35) levels were found to be higher in all disease stages compared to control. Relapses were associated with higher CSF NfH(SMI35) values compared with stable disease. NfH(SMI35) levels correlated with EDSS scores in patients with CIS and RRMS (r(s) = 0.33, p = 0.001), and during relapse (r(s) = 0.35, p = 0.01); the correlation was most prominent in RRMS during relapse (r(s) = 0.54, p = 0.01). This was not the case for any of the other CSF markers examined. Conclusions: Neuronal loss is a feature of aging, and the age-dependent increase of CSF NfH(SMI35) suggests that this loss accelerates over time. For MS, increased NfH(SMI35) levels reflect the superimposed presence of further neurodegenerative processes. Evaluation of NfH(SMI35) levels is likely to provide a useful surrogate for measuring the rate of neurodegeneration in MS. Furthermore, the dissociation of NfH(SMI35) levels with biomarkers of inflammation suggests that the mechanisms responsible for their production are at least partly independent. Neurology (R) 2011;76:1206-1213
引用
收藏
页码:1206 / 1213
页数:8
相关论文
共 50 条
  • [1] Serum neurofilament light chain captures and predicts disability progression independent of relapses (pira) in multiple sclerosis
    Lorscheider, J.
    Benkert, P.
    Yaldizli, O.
    Disanto, G.
    Oechtering, J.
    Schadelin, S.
    Wurfel, J.
    Chan, A.
    Achtnichts, L.
    Findling, O.
    Derfuss, T.
    Kropshofer, H.
    Orleth, A.
    Fischer-Barnicol, B.
    Maceski, A.
    Rey, D.
    Zadic, S.
    Mueller, C.
    Aeschbacher, S.
    Waubant, E.
    Oksenberg, J.
    Wellmann, S.
    Wiendl, H.
    Kappos, L.
    Salmen, A.
    Hoepner, R.
    Lalive, P.
    Du Pasquier, R.
    Pot, C.
    Maggi, P.
    Zecca, C.
    Naegelin, Y.
    Mueller, S.
    Hrusovsky, K.
    Berger, K.
    Conen, D.
    Barakovic, M.
    Sinnecker, T.
    Gobbi, C.
    Granziera, C.
    Leppert, D.
    Kuhle, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 191 - 192
  • [2] Neurofilament heavy chain in secondary progressive multiple sclerosis
    De Angelis, Floriana
    Ammoscato, Francesca
    Parker, Richard A.
    Plantone, Domenico
    Doshi, Anisha
    John, Nevin A.
    Williams, Thomas
    Stutters, Jonathan
    Macmanus, Dave
    Schmierer, Klaus
    Barkhof, Frederik
    Weir, Christopher J.
    Giovannoni, Gavin
    Chataway, Jeremy
    Gnanapavan, Sharmilee
    MS SMART Trial Investigators
    MULTIPLE SCLEROSIS JOURNAL, 2025, 31 (03) : 303 - 313
  • [3] Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
    Abdelhak, Ahmed
    Benkert, Pascal
    Schaedelin, Sabine
    Boscardin, W. John
    Cordano, Christian
    Oechtering, Johanna
    Ananth, Kirtana
    Granziera, Cristina
    Melie-Garcia, Lester
    Montes, Shivany Condor
    Beaudry-Richard, Alexandra
    Achtnichts, Lutz
    Oertel, Frederike C.
    Lalive, Patrice H.
    Leppert, David
    Mueller, Stefanie
    Henry, Roland G.
    Pot, Caroline
    Matthias, Amandine
    Salmen, Anke
    Oksenberg, Jorge R.
    Disanto, Giulio
    Zecca, Chiara
    D'Souza, Marcus
    Du Pasquier, Renaud
    Bridel, Claire
    Gobbi, Claudio
    Kappos, Ludwig
    Hauser, Stephen L.
    Cree, Bruce A. C.
    Kuhle, Jens
    Green, Ari J.
    JAMA NEUROLOGY, 2023, 80 (12) : 1317 - 1325
  • [4] Neurofilament light chain antibodies are correlated to disability in multiple sclerosis
    Burgal, M
    Garcia, S
    Hernández, A
    Lafuente, E
    Martinez, I
    Casanova, B
    Coret, F
    Bosco, I
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S166 - S166
  • [5] High CSF-neurofilament heavy chain levels in neuromyelitis optica: distinction from multiple sclerosis
    Fujihara, K.
    Miyazawa, I.
    Nakashima, I.
    Petzold, A.
    Sato, S.
    Itoyama, Y.
    MULTIPLE SCLEROSIS, 2006, 12 : S226 - S226
  • [6] Contribution of relapses to disability in multiple sclerosis
    C. Hirst
    G. Ingram
    O. Pearson
    T. Pickersgill
    N. Scolding
    N. Robertson
    Journal of Neurology, 2008, 255 : 280 - 287
  • [7] Relapses in multiple sclerosis: Relationship to disability
    Goodin, Douglas S.
    Reder, Anthony T.
    Bermel, Robert A.
    Cutter, Gary R.
    Fox, Robert J.
    John, Gareth R.
    Lublin, Fred D.
    Lucchinetti, Claudia F.
    Miller, Aaron E.
    Pelletier, Daniel
    Racke, Michael K.
    Trapp, Bruce D.
    Vartanian, Timothy
    Waubant, Emmanuelle
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 6 : 10 - 20
  • [8] Serum Neurofilament Light Chain for Multiple Sclerosis Relapses Too Little Too Late?
    Silbermann, Elizabeth
    Spain, Rebecca I.
    NEUROLOGY, 2024, 102 (09)
  • [9] Contribution of relapses to disability in multiple sclerosis
    Hirst, Claire
    Ingram, Gillian
    Pearson, Owen
    Pickersgill, Trevor
    Scolding, Neil
    Robertson, Neil
    JOURNAL OF NEUROLOGY, 2008, 255 (02) : 280 - 287
  • [10] Neurofilament Light Chain Correlates with Disease Activity while Both Neurofilament Light Chain and Glial Fibrillary Acidic Protein Associate with Disability in Pediatric Multiple Sclerosis
    Saucier, L.
    Healy, B. C.
    Saxena, S.
    Sanon, E. D.
    Saraceno, T. J.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 232 - 233